3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lung Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Fallopian Tube Neoplasms
7
Ovarian Neoplasms
6
Colorectal Neoplasms
5
Urinary Bladder Neoplasms
4
Pancreatic Neoplasms
4
Melanoma
4
Carcinoma, Hepatocellular
4
Lymphoma, Large B-Cell, Diffuse
3
Glioblastoma
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Brain Neoplasms
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
Multiple Myeloma
2
Lymphoid Interstitial Pneumonia
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma
2
Burkitt Lymphoma
2
Brenner Tumor
2
Breast Neoplasms
2
Interventions
pembrolizumab
15
Nivolumab
10
avelumab
9
atezolizumab
8
Gemcitabine
8
Cisplatin
8
Magnetic Resonance Spectroscopy
6
durvalumab
5
Specimen Handling
5
Docetaxel
5
Carboplatin
5
Paclitaxel
4
Ipilimumab
4
tislelizumab
3
sacituzumab govitecan
3
enfortumab vedotin
3
Taxes
3
Pemetrexed
3
Mitomycin
3
eribulin
2
erdafitinib
2
cabozantinib
2
Doxorubicin
2
CTLA-4 Antigen
2
ALT-803
2
zimberelimab
1
veliparib
1
urelumab
1
tazemetostat
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Transitional Cell
×
Disulfides
×
Clear all
NCT05154994
2026-05-07
RESOLVE
University of Utah
Phase 1
Active not recruiting
9 enrolled